Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Up 11.0% in March

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 62,800 shares, a growth of 11.0% from the March 15th total of 56,600 shares. Based on an average daily volume of 76,600 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.5% of the company’s shares are sold short.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in Hepion Pharmaceuticals in the fourth quarter valued at approximately $41,000. Envestnet Asset Management Inc. raised its holdings in Hepion Pharmaceuticals by 45.8% in the third quarter. Envestnet Asset Management Inc. now owns 87,541 shares of the company’s stock valued at $44,000 after acquiring an additional 27,487 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Hepion Pharmaceuticals by 5.8% in the fourth quarter. Renaissance Technologies LLC now owns 245,600 shares of the company’s stock valued at $74,000 after acquiring an additional 13,500 shares in the last quarter. State Street Corp raised its holdings in Hepion Pharmaceuticals by 8.1% in the first quarter. State Street Corp now owns 348,910 shares of the company’s stock valued at $450,000 after acquiring an additional 26,194 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in Hepion Pharmaceuticals by 0.3% in the first quarter. BlackRock Inc. now owns 1,602,772 shares of the company’s stock valued at $1,245,000 after acquiring an additional 5,206 shares in the last quarter. Hedge funds and other institutional investors own 17.24% of the company’s stock.

Hepion Pharmaceuticals Stock Down 6.4 %

Shares of HEPA stock opened at $2.04 on Wednesday. The company has a 50-day moving average of $2.32 and a two-hundred day moving average of $2.99. Hepion Pharmaceuticals has a 1-year low of $1.49 and a 1-year high of $20.66.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.